The First Frontier: Digital Biomarkers for Neurodegenerative Disorders

Current measures of neurodegenerative diseases are highly subjective and based on episodic visits. Consequently, drug development decisions rely on sparse, subjective data, which have led to the conduct of large-scale phase 3 trials of drugs that are likely not effective. Such failures are costly, d...

Full description

Saved in:
Bibliographic Details
Published inDigital biomarkers Vol. 1; no. 1; pp. 6 - 13
Main Authors Dorsey, E. Ray, Papapetropoulos, Spyros, Xiong, Mulin, Kieburtz, Karl
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.09.2017
Subjects
Alzheimer's disease
Amyotrophic lateral sclerosis
Bias
Biomarkers
Clinical trials
Costs
Drug development
Failure
Neurology
Parkinson's disease
Patients
Success
Viewpoint – Review
United States > US
Neurodegenerative diseases
Alzheimer disease
Technology
Biosensing techniques
Huntington disease
Therapeutics
Parkinson disease
Biomarkers
Amyotrophic lateral sclerosis
Research
Smartphone
Outcome assessment
Online AccessGet full text

Cover

More Information
Summary:Current measures of neurodegenerative diseases are highly subjective and based on episodic visits. Consequently, drug development decisions rely on sparse, subjective data, which have led to the conduct of large-scale phase 3 trials of drugs that are likely not effective. Such failures are costly, deter future investment, and hinder the development of treatments. Given the lack of reliable physiological biomarkers, digital biomarkers may help to address current shortcomings. Objective, high-frequency data can guide critical decision-making in therapeutic development and allow for a more efficient evaluation of therapies of increasingly common disorders.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2504-110X
2504-110X
DOI:10.1159/000477383